Related Experiment Video

Updated: Feb 4, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.1K

GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma

Praveena Velpurisiva1, Brandon P Piel2, Jack Lepine3

  • 1Department of Biomedical Engineering and Biotechnology, University of Massachusetts, Lowell, MA 01854, USA. Praveena_velpurisiva@uml.edu.

Bioengineering (Basel, Switzerland)
|October 12, 2018
PubMed

Insights

This study shows that encapsulating the Polo-like kinase 1 (PLK-1) inhibitor GSK461364A (GSK) in nanoparticles enhances its effectiveness against glioblastoma cells. This nanomedicine approach improves drug delivery, potentially reducing side effects at lower, effective doses.

Area of Science:

  • Oncology
  • Nanomedicine
  • Pharmacology

Background:

  • Glioblastoma Multiforme (GBM) is an aggressive brain cancer with poor patient prognosis and limited treatment options.
  • Current GBM treatments cause significant side effects, impacting patient lifespan and quality of life.
  • Nanomedicine offers targeted drug delivery to tumors, potentially improving efficacy and reducing systemic toxicity.

Purpose of the Study:

  • To evaluate the efficacy of GSK461364A (GSK), a Polo-like kinase 1 (PLK-1) inhibitor, for glioblastoma treatment.
  • To investigate the potential of encapsulating GSK within PLGA-PEG nanoparticles for improved glioblastoma therapy.
  • To assess the dose-dependent and time-dependent effects of GSK on glioblastoma cell viability.

Main Methods:

  • Utilized U87-MG glioblastoma cell lines for in vitro studies.
  • Administered varying concentrations of GSK461364A (GSK) to assess its time-dependent action and impact on cell viability.
  • Formulated and tested PLGA-PEG nanoparticles (NPs) loaded with GSK, comparing their efficacy to free GSK.

Main Results:

  • GSK demonstrated time-dependent cytotoxic effects on U87-MG cells across all tested concentrations.
  • Low concentrations of GSK (nanomolar to lower micromolar) induced a significant 15-20% decrease in cell viability via apoptosis.
  • PLGA-PEG nanoparticles encapsulating GSK significantly reduced tumor cell viability compared to free GSK, indicating enhanced efficacy.

Conclusions:

  • PLGA-PEG nanoparticles effectively encapsulate GSK, improving its therapeutic potential for glioblastoma.
  • This nanocarrier system allows for effective cancer treatment at lower GSK concentrations, potentially mitigating toxicity and side effects.
  • This study presents the first report of a PLK-1 inhibitor (GSK) encapsulated in a nanocarrier for cancer therapy applications.
Keywords:
GSK461364AGlioblastoma MultiformeU-87 MGcytotoxicityenhanced permeability and retentiononcologyoncomedicinepolo-like kinase inhibitorpolymeric nanoparticles

More Related Videos

Translational Orthotopic Models of Glioblastoma Multiforme07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.7K
Isolation and Expansion of Human Glioblastoma Multiforme Tumor Cells Using the Neurosphere Assay09:24

Isolation and Expansion of Human Glioblastoma Multiforme Tumor Cells Using the Neurosphere Assay

Published on: October 30, 2011

30.5K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
534
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.1K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
605
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.6K